Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 290368, 6 pages
http://dx.doi.org/10.1155/2015/290368
Research Article

The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells

Laboratory of Cancer Stem Cell, Stem Cell Research Center, University of Pittsburgh, Pittsburgh, PA 15217, USA

Received 24 November 2014; Accepted 31 January 2015

Academic Editor: Genichiro Ishii

Copyright © 2015 Xiaodong Mu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Bacci, A. Briccoli, M. Mercuri et al., “Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy,” Journal of Chemotherapy, vol. 10, no. 1, pp. 69–76, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Bacci, S. Ferrari, M. Mercuri et al., “Predictive factors for local recurrence in osteosarcoma 540 Patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy,” Acta Orthopaedica Scandinavica, vol. 69, no. 3, pp. 230–236, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Bacci, S. Ferrari, M. Mercuri et al., “Neoadjuvant chemotherapy for extremity osteosarcoma: preliminary results of the Rizzoli's 4th study,” Acta Oncologica, vol. 37, no. 1, pp. 41–48, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. S. S. Bielack, B. Kempf-Bielack, G. Delling et al., “Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 776–790, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Kager, U. Pötschger, and S. Bielack, “Review of mifamurtide in the treatment of patients with osteosarcoma,” Therapeutics and Clinical Risk Management, vol. 6, pp. 279–286, 2010. View at Publisher · View at Google Scholar
  6. L. Kager, A. Zoubek, M. Dominkus et al., “Osteosarcoma in very young children: experience of the Cooperative Osteosarcoma Study Group,” Cancer, vol. 116, no. 22, pp. 5316–5324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Marina, M. Gebhardt, L. Teot, and R. Gorlick, “Biology and therapeutic advances for pediatric osteosarcoma,” Oncologist, vol. 9, no. 4, pp. 422–441, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. I. Bortolomai, S. Canevari, I. Facetti et al., “Tumor initiating cells: development and critical characterization of a model derived from the A431 carcinoma cell line forming spheres in suspension,” Cell Cycle, vol. 9, no. 6, pp. 1194–1206, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Khanna, J. Khan, P. Nguyen et al., “Metastasis-associated differences in gene expression in a murine model of osteosarcoma,” Cancer Research, vol. 61, no. 9, pp. 3750–3759, 2001. View at Google Scholar · View at Scopus
  10. C. Khanna, J. Prehn, C. Yeung, J. Caylor, M. Tsokos, and L. Helman, “An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential,” Clinical and Experimental Metastasis, vol. 18, no. 3, pp. 261–271, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. K. R. Weiss, G. M. Cooper, J. A. Jadlowiec, R. L. McGough III, and J. Huard, “VEGF and BMP expression in mouse osteosarcoma cells,” Clinical Orthopaedics and Related Research, vol. 450, pp. 111–117, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Greco, T. Schott, X. Mu et al., “ALDH activity correlates with metastatic potential in primary sarcomas of bone,” Journal of Cancer Therapy, vol. 5, no. 4, pp. 331–338, 2014. View at Publisher · View at Google Scholar
  13. X. Mu, C. Isaac, N. Greco, J. Huard, and K. Weiss, “Notch signaling is associated with ALDH activity and an aggressive metastatic phenotype in murine osteosarcoma cells,” Frontiers in Oncology, vol. 3, article 143, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. X. Mu, C. Isaac, T. Schott, J. Huard, and K. Weiss, “Rapamycin inhibits ALDH activity, resistance to oxidative stress, and metastatic potential in murine osteosarcoma cells,” Sarcoma, vol. 2013, Article ID 480713, 11 pages, 2013. View at Publisher · View at Google Scholar
  15. X. Mu, B. Sultankulov, R. Agarwal et al., “Chick embryo extract demethylates tumor suppressor genes in osteosarcoma cells,” Clinical Orthopaedics and Related Research, vol. 472, no. 3, pp. 865–873, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Ropero and M. Esteller, “The role of histone deacetylases (HDACs) in human cancer,” Molecular Oncology, vol. 1, no. 1, pp. 19–25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. P. E. Burger, R. Gupta, X. Xiong et al., “High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells,” Stem Cells, vol. 27, no. 9, pp. 2220–2228, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Charafe-Jauffret, C. Ginestier, F. Iovino et al., “Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer,” Clinical Cancer Research, vol. 16, no. 1, pp. 45–55, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. R. Clay, M. Tabor, J. H. Owen et al., “Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase,” Head & Neck, vol. 32, no. 9, pp. 1195–1201, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. A. K. Croker, D. Goodale, J. Chu et al., “High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability,” Journal of Cellular and Molecular Medicine, vol. 13, no. 8, pp. 2236–2252, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Deng, X. Yang, H. Lassus et al., “Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers,” PLoS ONE, vol. 5, no. 4, Article ID e10277, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Ginestier, M. H. Hur, E. Charafe-Jauffret et al., “ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome,” Cell Stem Cell, vol. 1, no. 5, pp. 555–567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem cells, cancer, and cancer stem cells,” Nature, vol. 414, no. 6859, pp. 105–111, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. L. A. Lambert, N. Qiao, K. K. Hunt et al., “Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model,” Cancer Research, vol. 68, no. 19, pp. 7966–7974, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Sotgia, D. Whitaker-Menezes, U. E. Martinez-Outschoorn et al., “Mitochondria ‘fuel’ breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells,” Cell Cycle, vol. 11, no. 23, pp. 4390–4401, 2012. View at Publisher · View at Google Scholar · View at Scopus